At Sangre AgroTech, we all come to work every day because we are focused on the development and application of cannabis-derived compounds for the treatment of human disease. Targeting cannabis-derived molecules which stimulate the endocannabinoid system, we are developing the required scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. Yes, medicines.
Sangre AgroTech is comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available.
To quote our President and Chief Science Officer, Dr. Patrick Williams, “A comprehensive understanding of the annotated genome of a variety of cannabis strains will provide the blueprints for the development of significant medicinal products for the treatment of human diseases such as pediatric brain cancer, PTSD, epilepsy, chronic pain, and Crohn’s disease.” We are dedicated to finding treatments and medical cures utilizing the Cannabaceae plant family.